The UK and US have hammered out a significant commercial pact that will ensure no tariffs on British medicine shipments being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to raise expenditure on drugs through the NHS. This commitment secures that duties on these key exports will stay at zero for a timeframe of 36 months.
This agreement comes after previous statements to hike duties on branded pharmaceutical products, with figures mentioned as high as 100%.
"This arrangement with the Britain strengthens the global environment for innovative medicines and introduces long-overdue balance to transatlantic drug exports," an announcement declared.
Trade Impact
Drugs are one of the Britain's largest goods shipped to the America, which is easily the largest buyer for leading UK drugmakers.
Export figures indicate that in the one-year period prior to the third quarter, the UK exported drugs worth £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that span.
"This agreement safeguards jobs, boosts funding and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The pact entails several notable changes from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates were more than twenty percent.
Broader Context
The pact comes amid a long-running dispute between the sector and the ministers over spending levels and regulatory access.
These tensions were exacerbated by assertions that US patients were charged significantly more for the same drugs than consumers in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
